The Efficacy, Pharmacokinetics, and Safety of a Nevirapine to Rilpivirine Switch in Virologically Suppressed HIV-1–Infected Patients is established

PROF.DRRAM ,HIV/AIDS,SEX Diseases, Hepatitis .& Deaddiction Expert 
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE. 
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar 
FOLLOW ON TWITTER:www.twitter.com/profdrram
Nevirapine is now no more used as HAART OR ARV medicines as it result in Stevenson jhonson syndrome or drug toxicity as Toxic epermonecrolysis syndrome beside hepatitis but even those tolerate and if viral count is less then subsituting it with another NNRTI as Rilprivine is very good and it is less toxic and better control viral load ,it is more used with tenofovir and emtricitabine where as we were using NEVIRAPINE first with Stavudine and later with Zidovudine and lamivudine or rarely with Abacavir.
This prospective, open-label nonrandomized controlled trial evaluated the efficacy, safety, and pharmacokinetics of substituting nevirapine/emtricitabine/tenofovir for rilpivirine/emtricitabine/tenofovir in 50 suppressed HIV-1 switchers. 
One hundred thirty-nine nonswitchers remained on nevirapine as controls. Week 12 HIV-1 RNA was <50 copies per milliliter in 92.0% of switchers and was <50 copies per milliliter at week 24 in 88.0% of switchers and 90.6% of nonswitchers (difference 2.6%, 95% confidence interval: −7.6% to 12.8%). Week 3 geometric mean nevirapine concentration was undetectable and week 1 geometric mean rilpivirine concentration (0.083 mg/L) was comparable with phase 3 trial (P = 0.747). Substituting nevirapine for rilpivirine resulted in ongoing virological suppression and did not have clinically relevant pharmacokinetic effects by cytochrome P450 interactions.